Entera Bio Presents New Phase 2 Data at NAMS Annual Meeting.

Entera Bio Ltd. will present new clinical data from its Phase 2 trial of EB613 at the North American Menopause Society (NAMS) 2025 Annual Meeting. The data will focus on bone mineral density outcomes in early postmenopausal women with low bone mass or osteoporosis over six months. This population is at rising risk but few receive anabolic therapy, which can rebuild bone. The analysis will examine the potential role of EB613 earlier in the treatment journey.

Entera Bio Ltd. (NASDAQ: ENTX) is set to present new clinical data from its Phase 2 trial of EB613 at the North American Menopause Society (NAMS) 2025 Annual Meeting, taking place October 21-25, 2025, in Orlando, Florida. The data will focus on bone mineral density (BMD) outcomes in early postmenopausal women with low bone mass or osteoporosis over six months. This population is at rising risk but few receive anabolic therapy, which can rebuild bone. The analysis will examine the potential role of EB613 earlier in the treatment journey.

The presentation will be a poster session on October 23, 2025, from 6:15 PM to 7:15 PM in the Windemere Exhibit Hall. The poster (P-66) will report six-month BMD outcomes in early postmenopausal women with low bone mass or osteoporosis, evaluating oral PTH[1-34] tablets as a potential anabolic option earlier in treatment where injectables are underutilized. This marks Entera’s first presentation at NAMS.

EB613, an oral PTH(1-34) tablet, is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. It completed a phase 2, 6-month, 161-patient, placebo-controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD, according to a Stocktitan report.

Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs. The company leverages its proprietary technology platform (N-Tab™) to develop products such as EB613, which aims to transform the standard of care for osteoporosis patients. Entera Bio is also developing other oral peptide programs targeting GLP-1, GLP-2, and oxyntomodulin for obesity and metabolic conditions, and rare malabsorption conditions such as short bowel syndrome .

The presentation at NAMS will be an opportunity for the medical community to learn more about the potential of EB613 in treating osteoporosis earlier in the treatment journey, where injectable options remain underutilized. This could significantly broaden access to anabolic therapy for the over 200 million women worldwide living with osteoporosis.